ADVA-OPTICAL-NETWORKING
9.11.2021 09:02:10 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5400 TimeCard™ , enabling operators of data center network infrastructure and 5G open RAN architectures to achieve highly accurate and reliable distribution and synchronization of time. Built on the OSA 5400 SyncModule™ , ADVA’s new PCIe card brings sophisticated timing capabilities to any open compute server, transforming it into a precise and stable PTP grandmaster, boundary clock, slave clock or NTP server. The OSA 5400 TimeCard™ is the market’s first solution developed to the framework of the Open Compute Project’s (OCP) Time Appliance Project (TAP) and enhanced with both PTP and NTP functions. With advanced synchronization capabilities, it solves a key challenge for network operators as they virtualize their infrastructure and replace purpose-built hardware with standard servers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005255/en/
“Timing in data centers and other open compute cases like 5G open RAN is becoming increasingly crucial as a growing number of applications require new levels of performance. But the sub-microsecond synchronization needed for efficient resource sharing is something that open compute servers often cannot provide. Open compute customers need a way to inject the most advanced synchronization capabilities into their white box hardware. That’s why we’ve engineered our OSA 5400 TimeCard™. It brings our experience in network and application synchronization to open compute servers as well as open RAN equipment, enabling a whole new group of customers to benefit from our unique expertise,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our feature-rich OSA 5400 TimeCard™ meets and goes beyond OCP-TAP specifications. For data centers, finance and 5G infrastructure, it’s the key to bringing packet time distribution to the edge and access network.”
Developed specifically to OCP-TAP specifications, ADVA’s new OSA 5400 TimeCard™ is enhanced with an integrated GNSS receiver, PTP, NTP, PTP assurance, GNSS assurance and mitigation engines, as well as full sync management functionality. Easily plugged into a free PCIe slot of a standard open compute server or PC, it delivers extremely robust and precise synchronization. It offers a wide range of oscillator options to cost-effectively meet different levels of holdover requirements. Unlike competing solutions, the OSA 5400 TimeCard™ is designed for simplicity and assured operations. Its powerful control interface provides comprehensive device information as well as data on the performance of the timing network. The OSA 5400 TimeCard™ provides transparent assurance and can be managed by ADVA’s Ensemble Sync Director . Comprehensive visibility of the timing infrastructure puts operational teams in complete control, even with no specialist expertise in network synchronization.
“In a wide range of industries, the need is now being recognized for highly precise and stable synchronization of time and frequency across packet networks. But the race to roll our cost-effective standard hardware and embrace the advantages of server virtualization often leaves a timing gap. As strict synchronization is now vital for more and more applications, operators urgently need an efficient way to bring tight timing to open compute servers. Our OSA 5400 TimeCard™ is the answer,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Our PCIe pluggable card will empower data center operators, enterprises, utilities, broadcast networks, financial networks and 5G mobile service providers to harness time-sensitive applications through reliable, scalable and high-accuracy timing.”
Further details on the OSA 5400 TimeCard™ are available in these slides: https://adva.li/osa-5400-timecard-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005255/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
